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ABSTRACT 
 
 
Study of antibody specificities can help design better vaccines. This project 
focused on investigating the binding properties of a panel of rabbit monoclonal antibodies 
(RmAbs) elicited by a novel vaccine consisting of an HIV-1 gp120 AE consensus DNA-
prime injection followed by a boost vaccine containing artificial gp120 AE consensus 
protein. Recombinant gp120 proteins from several isolates in clade AE were produced by 
transient transfection of 293F cells with DNA plasmids expressing individual AE 
gp120’s. The gp120 proteins were purified by lectin beads, then verified for expression 
using SDS-PAGE and Western blots before being used as coats for ELISA to examine 
the reactivity of RmAb to these expressed gp120 proteins. Amino acid sequences of these 
gp120 proteins were used to map the potential epitopes recognized by the rabbit 
monoclonal antibodies.  The data show that the novel vaccine was successful in 
producing rabbit monoclonal antibodies against several clade AE HIV-1 gp120 proteins.  
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BACKGROUND 
 
 
I. Human Immunodeficiency Virus  
 
HIV Overview 
 
 The Human Immunodeficiency Virus (HIV) is a retrovirus that infects and 
destroys CD4
+
 lymphocytes.  HIV causes a fatal condition known as Acquired 
Immunodeficiency Syndrome (AIDS), which results from the destruction of the immune 
system by an HIV infection (Kwong et al., 1998). In 2011, 34.2 million people were 
living with HIV worldwide, and 1.7 million deaths were caused by HIV. There is no 
vaccine available, but current treatment include antiretroviral therapy, which does not 
cure HIV but can improve quality of life and increase life expectancy (UNAIDS, 2013).  
 
HIV Viral Subtypes 
 
There are two types of HIV, HIV-1 and HIV-2.  HIV-1 is responsible for the 
worldwide pandemic, while HIV-2 is found primarily in some West African countries, 
but is rarely found elsewhere in the world. As HIV-1 is the type responsible for most 
cases of HIV infection worldwide, this project, much like most HIV vaccine research, 
focuses on vaccines against HIV-1 (McCutchan, 2006). 
HIV-1 is further divided into subgroups M, N, and O. Of these three subgroups, 
the large majority of HIV-1 infections are in subgroup M. The M group of HIV-1 has 
been found to contain ten clades (or subtypes) dictated by differences in their genetic 
sequences, which are termed A, B C, D, E, F, G, H, J, and K. There are also circulating 
recombinant forms (CRFs) of these clades where two clades combine to form a new 
clade, for example A and B combine to form AB. In order to be recognized as a CRF, an 
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identical recombinant virus must be identified in at least three epidemiologically unlinked 
individuals and fully characterized by genetic sequencing. This project will focus on the 
recombinant CRF AE, which is a recombinant of HIV-1 A and E. CRF AE is prevalent in 
Southeast Asia (Buonaguro et al., 2007) (Figure-1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: HIV-1 Viral Clades and Their Global Distribution (McCutchan, 2006) 
 
 
II. HIV-1 Envelope 
 
HIV-1 is an enveloped fusogenic virus, and the envelope region (env) of the HIV-
1 viron serves a critical role as a receptor. The entry of HIV-1 into the host cell is 
dependent upon a series of interactions involving viral envelope surface glycoproteins. 
These envelope glycoproteins are displayed on the surface of the viral envelope as 
trimeric spikes (Figure-2) which interact with the CD4 glycoprotein and chemokine 
receptors CCR5 and CXCR4 on the surface of the host cell to facilitate cellular entry 
(Kwong et al., 1998). These trimeric envelope spikes are composed of three copies of an 
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extracellular glycoprotein termed gp120, and three copies of a transmembrane 
glycoprotein termed gp41 (Zhou et al., 2007). Each gp120 molecule is non-covalently 
associated with a gp41 molecule, which anchors the complex to the viral membrane 
(Kwong et al., 1998).  
 
 
Figure 2: HIV-1 trimeric envelope spike showing gp120, gp41, and the 
binding sites of known neutralizing antibodies (Burton et al., 2004) 
 
 
HIV-1 gp41 regulates membrane fusion with the host cell, and contains the 
domain responsible for trimerization of the glycoprotein spikes. The extracellular gp120 
contains domains for receptor binding to CD4
+
 and CCR5/CXCR4 (Dey et al., 2007). 
The amino acid sequence of the gp120 envelope region contains five variable regions, 
termed V1-V5, which are dispersed between conserved regions of the sequence. The 
conserved regions contain the amino acid domains responsible for the viral receptor 
binding, as well as interactions with gp41 (Kwong et al., 1998). While the HIV-1 env is 
highly diverse due to extensive variable regions in the amino acid sequence, HIV-1 env 
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must maintain some conserved determinants to retain the ability to bind the CD4+ 
receptor for cellular entry (Zhou et al., 2007). The trimeric envelope spike is the only 
viral gene product on the surface of HIV-1 and contains some conserved sequences 
required for host cell entry, making this glycoprotein complex an ideal target for 
neutralizing antibodies and vaccine development (Dey et al., 2007). 
 
III. HIV-1 Vaccine Progress 
 
HIV-1 is a complex virus, with extreme genetic diversity and conformational 
hindrance of neutralization attempts by the immune system. It is difficult for one 
antibody to block HIV-1 isolates with broad diversity. Protection against an HIV-1 
infection requires a preventative vaccine. However, candidate HIV-1 vaccines have not 
been able to elicit potent neutralizing antibodies against different subtypes. It is evident 
that the production of effective vaccine against HIV-1 will be a challenge, and will likely 
involve novel methods of vaccine development. 
 
Heterologous Prime-Boost Vaccine 
 
 Many vaccines require multiple immunizations to fully protect against disease, 
and studies have shown that HIV-1 will be no exception. These multiple immunizations 
are termed prime-boost, and can be homologous (same vaccines) or heterologous 
(different vaccines). Homologous prime-boost vaccines are multiple immunizations of 
the same type of vaccines, which applies to vaccines such as live attenuated vaccines, 
inactivated vaccines, and polysaccharide vaccines. Heterologous prime-boost vaccines 
are multiple immunizations with the same antigen but delivered by different types of 
vaccines, which can be applied to more novel vaccines such as DNA or viral vector 
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vaccines (Lu, 2009). While heterologous prime-boost vaccines are a relatively new 
development in the vaccine field, in many cases were more effective than homologous 
prime-boost vaccines (Ramshaw and Ramsey, 2009). A successful HIV-1 vaccine will 
need to stimulate the production of neutralizing antibodies and generate a cellular T cell 
immune response. The concept of an HIV-1 heterologous prime-boost vaccine 
incorporating both of these elements seems more promising than a homologous prime-
boost vaccine with just one of the elements. Evidence from recent vaccine studies 
supports this idea (Lu, 2009).  
 
VaxGen AIDSVAX B/E HIV-1 Vaccine Trial 
 
One of the first major HIV-1 vaccine trials was the VaxGen AIDSVAX B/E 
vaccine trial in Thailand. The major HIV-1 subtypes in Thailand were subtype B among 
injection drug users, and sexually transmitted subtype E (which would later become CRF 
AE). The VaxGen vaccine administered in this trial, AIDSVAX B/E, was a homologous 
prime-boost vaccine containing two recombinant gp120 (rgp120) HIV-1 antigens from 
the prevalent HIV-1 subtypes. One antigen was a CXCR4-dependent subtype B strain 
developed in the laboratory, and the other antigen was a CCR-5-dependent subtype AE 
primary isolate (Pitisuttithum et al., 2006). As the extracellular portion of the trimeric 
envelope spike, gp120 is capable of triggering natural antibody response in an HIV-1 
infection, eliciting both neutralizing and non-neutralizing antibodies. Neutralizing 
antibodies, which effectively act to neutralize the CD4+ receptor binding function of 
gp120, are able to recognize variable regions and conserved regions of the gp120 amino 
acid sequence (Wyatt et al., 1998). A total of 2,546 participants were enrolled in this trial 
and were immunized with either AIDSVAX B/E at months 0, 1, 6, 12, 18, 24, and 36. 
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However, this vaccine did not produce efficacy against either HIV-1 subtype B or 
subtype E, and therefore did not prevent or delay HIV-1 infection (Pitisuttithum et al., 
2006).  
 
Merck STEP HIV-1 Vaccine Trial 
 
Following the failure of the VaxGen trial, the focus of HIV vaccine research 
shifted away from inducing sterilizing immunity and more towards controlling viral load. 
A vaccine involving T-cell mediated immunity was therefore expected to elicit strong 
cellular immunity against HIV. This was the basis for the Merck STEP HIV vaccine trial. 
HIV antigens expressed in replication-deficient adenoviral vector vaccines were found to 
be capable of eliciting T-cell response in humans. The STEP HIV vaccine trial used a 
recombinant adenovirus serotype 5 (rAD5)-based vaccine. In this trial, 3,000 uninfected 
individuals were vaccinated with three rAD5 vectors, each expressing a different HIV 
gene: Ad5-gag, Ad5-pol, and Ad5-Nef. Each individual was immunized three times over 
a course of 26 weeks with either the MRKAd5 gag/pol/nef HIV-1 vaccine or the placebo 
(Selaky, 2008; Buchbinder et al., 2008). The determination of whether an individual 
received the rAD5 vaccine or the placebo was done in a randomized fashion with a 1:1 
ratio. Shockingly, this vaccine trial resulted in an overall HIV-1 acquisition in 5.1% of 
men that received the vaccine, and 2.3% of men that received the placebo. Only one 
female participant acquired an HIV infection, so the vaccine efficacy analysis was limited 
to the male participants. The efficacy analysis following this trial was the first evaluation 
of a cell-mediated immunity (CMI)-based vaccine. Based on this analysis, it was 
determined that this vaccine did not protect against HIV-1 infection nor lower the HIV-1 
viral load in infected participants (Buchbinder et al., 2008).  
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RV144 HIV-1 Vaccine Trial 
 
The concept of using a heterologous prime-boost vaccine was used in the first 
partially successful HIV-1 vaccine trial. The RV144 phase 3 trial in Thailand used a 
canary pox vector vaccine prime ALVAC-HIV (vCP1521) with subsequent gp120 
vaccine AIDSVAX B/E boosts. This trial involved at total of 16,402 participants who 
were vaccinated at weeks 0, 4, 12, and 24 with ALVAC and boosted with AIDSVAX B/E 
at weeks 12 and 24. The estimated efficacy of the vaccine regimen against HIV-1 was 
31.2% over a period of 42 months. The results of this study showed a statistically 
significant reduction in HIV-1 infection in the participants that received the vaccine 
compared to the placebo (Rerks-Ngarm et al., 2009). Further analysis of the results of the 
RV144 trial showed a key correlation between serum antibody binding and the V2 
variable region of the HIV-1 envelope glycoprotein. This correlation provides evidence 
that antibodies are a necessary component of a successful HIV-1 vaccine (Rolland et al., 
2012). 
 
Lu Lab Contribution 
 
The Nucleic Acid Vaccine Lab and its Principal Investigator Shan Lu are working 
to create a DNA vaccine expressing HIV-1 AE gp120 proteins that will elicit a 
neutralizing antibody response and protect against HIV-1 infection. Previous studies 
reported by the Lu Lab have shown that polyvalent Env DNA prime followed by gp120 
boost vaccines are capable of generating neutralizing antibodies against HIV-1 (Wang et 
al., 2005; Wang et al., 2008). However, in previous studies, only polyclonal antibody 
responses were studied, which is hard to identify specific epitopes within the HIV-1 
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envelope glycoprotein. The Lu Lab has currently focused their research on utilizing a 
monoclonal antibody approach elicited by vaccines to dissect the specificity of the 
antibody repertoire induced by their candidate vaccines.  
 
IV. Human Monoclonal Antibodies against HIV-1 
 
HIV-1 is extremely proficient at avoiding elimination and avoiding control of 
disease progression by both humoral and cell-mediated immune responses. However, an 
HIV-1 infection is capable of triggering the human immune system to produce antibodies 
against the invading virus. Serum antibodies directed against HIV-1 envelope gp120 can 
neutralize essential viral functions by binding to specific epitopes on the virion (Posner et 
al., 1991). The formation of neutralizing human monoclonal antibodies (HmAbs) 
generated as a result of an HIV-1 infection provide a useful tool in HIV-1 vaccine 
research, as they demonstrate that the human humoral system is capable of neutralizing 
the HIV-1 virus. As monoclonal antibodies, these HmAbs also allow any binding 
observations to be linked to the particular epitope recognized by the HmAb. However, 
neutralizing HmAbs are only found in 2-4% of the HIV-1 infected population after two to 
three years following the initial infection (Gray et al., 2011). Although HmAbs are an 
effective tool for studying the neutralization of HIV-1, a tool that is more readily 
available and cost effective, such as the use of rabbit monoclonal antibodies against HIV-
1, would be a much more efficient means for conducting this type of research. 
 
V. Rabbit Monoclonal Antibodies 
 
The Lu Lab has recently developed a new technology of generating rabbit 
monoclonal antibodies (RmAbs) elicited by an HIV-1 immunogen. Rabbits are an ideal 
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animal model for antibody studies because rabbit antibodies have a small amount of 
background reactivity and a large volume of immune sera. Vaccine trials using rabbits are 
also quicker and less costly than human vaccine trials. Monoclonal antibodies specifically 
bind to single epitopes, so the development of RmAbs against HIV-1 allow for antibody 
binding activity by the RmAbs to be mapped to particular sequences on the HIV-1 
immunogen. This novel technology will allow for a more definitive study of neutralizing 
antibody binding epitopes elicited by HIV-1 vaccines. 
The Lu Lab designed consensus nucleotide and protein sequences for HIV-1 clade 
AE antigens, in which every amino acid is the most frequently observed at each position 
in the alignment of global circulating clade AE isolates. To test the immunogenicity of 
this gp120 AE consensus vaccine, rabbits were inoculated three times with DNA 
encoding the gp120 AE consensus protein followed by twice gp120 AE consensus 
protein immunization. Analysis of immunized polyclonal rabbit sera has shown that this 
vaccine is able to elicit cross-clade binding antibody (Ab) and neutralizing Abs.  
To better dissect the quality of the Ab response to the consensus vaccine and 
protein boost, the Lu Lab used the technology of rabbit monoclonal antibodies (RmAbs) 
against HIV-1 gp120 protein. A panel of twenty-two RmAbs was generated from the sera 
of two different rabbits, 813 and 612. Rabbit 813 was immunized with the above 
gp120AE consensus vaccination regimen. Rabbit 612 was immunized with the same type 
of vaccination regimen, but received an HIV-1 JR-FL gp120 DNA prime vaccine (instead 
of the gp120AE consensus) and an HIV-1 JR-FL gp120 recombinant protein boost 
vaccine. The spleens from these two rabbits were used for the production of hybridoma 
cells to produce the RmAbs. Of the ten RmAbs that were used in the current study, two 
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of the RmAbs, 53 and 56, were from rabbit 612, and eight were from rabbit 813. These 
ten 813 RmAbs were used in this project to analyze their binding with a panel of clade 
AE HIV-1 gp120 proteins. This panel of RmAbs had diverse epitopes, including the C1, 
V3, C4, and C5 regions on the gp120 protein. This project will test whether these RmAbs 
of different specificity generated from a vaccine based on “artificial” consensus sequence 
of clade AE gp120 will also binds to gp120 proteins cloned from circulating clade AE 
virus. 
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PROJECT PURPOSE 
 
The overall objective of this project was to assist with the Lu Lab’s ongoing 
research in developing vaccines against HIV-1 by focusing on determining the binding 
properties of a panel of rabbit monoclonal antibodies elicited by a novel vaccine 
approach. The Lu Lab vaccine in rabbits used three injections with a consensus gp120 
AE consensus DNA vaccine followed by two injections of a gp120 AE consensus protein 
boost vaccine. The binding properties and possible epitope locations of the rabbit mAbs 
were tested in ELISAs using various expressed gp-120 clade AE HIV-1 gp120 proteins 
as coats. 
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METHODS 
 
The four main sections of this project were gp120 cell transfections, gp120 
protein purifications, ELISA assays using gp-120 proteins as coat, and RmAb sequence 
analysis. Transfections of 293F cells with gp120 DNA plasmids produced clade AE HIV-
1 gp120 proteins. The gp120 proteins were purified using lectin beads, and the success of 
the purification was confirmed by SDS-PAGE and Western blots. The binding profiles of 
the twelve RmAbs produced by the Lu Lab were tested by ELISA using the transfected 
gp120 proteins as the ELISA coating antigens. Then finally, an analysis was performed to 
compare HIV-1 AE gp120 protein sequence variations with the binding profiles of the 
RmAbs tested by ELISAs. 
 
gp120 DNA Preparations 
 
Nine full length env genes of clade AE were obtained from chronically HIV-1 
infected individuals from Duke University. The gene segments encoding the gp120 
region were produced by PCR from parental DNA, and were further subcloned into the 
expression vector.  gp120 DNA plasmid was produced in the HB101 strain of E. coli, 
then purified using the Qiagen Plasmid Mega Kit. 
 
gp120 Transfections 
 
The transfections were performed using human embryonic kidney 293F cells. The 
293F cells were cultured to about one million cells per mL. 250 µg of gp120 DNA was 
mixed with OPTIMEM media for each individual protein. Ten clade AE gp120 proteins 
were transfected: 620345.c01, 620345.c10, 703357.c02, 427299.c12, 816763.c02, 
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356272.c02, R2184.c04, R3265.c06, ChinaAE consensus, and AE consensus. 
Additionally, one clade B protein, JR-FL, was also transfected by the same method. The 
gp120 DNA was incubated in the media for five minutes, then 750 µg PEI was added to 
each sample and incubated for thirty minutes. After incubation, the DNA suspension for 
each individual gp120 protein was added to 293F cells. The supernatants containing each 
gp120 protein were harvested 72 hours after the transfection. 
 
gp120 Protein Purification 
Transfected cells were cultured to allow the expressed gp120 proteins to be 
secreted into the medium.  The eleven gp120 proteins were purified using lentil lectin 
Sepharose 4B beads. 20 mL of supernatant containing the secreted gp120 protein from 
the 293F transfection was concentrated to 1 mL using Millipore Centrifugal Filter Units 
for each protein. The solutions were incubated for 2 hours with lectin beads, then the 
proteins eluted with elution buffer. The concentrations of the purified gp120 proteins 
were determined by Nano-Drop. The purification of gp120 protein was confirmed by 
SDS-PAGE and Western blots. 
 
SDS-PAGE 
 
SDS-PAGE was used to confirm the purification of the gp120 antigens from the 
supernatant of the transfected 293F cells. The purified gp120 proteins from the 
transfected 293F cells were denatured with 6X SDS and loaded onto the gel at a 
concentration of  5 µg/mL. Protein marker p77095 was included in the gel for reference. 
The SDS-PAGE gels were stained with Coomassie blue.  
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Western Blot 
A Western blot was performed to confirm the expression of the purified gp120 
proteins from the supernatant of the transfected 293F cells. The purified gp120 proteins 
were blotted at a concentration of 0.1 µg/mL using SDS-PAGE and a PDVF membrane. 
The rabbit mAb R16 was used as primary antibody for the Western. Protein marker 
p77095 was included in the blot for reference. Membrane blocking was done using 0.2% 
I-Block. The membrane was incubated for 1 hour with rabbit serum at 1:500 dilution 
from RmAb 16 isolated from rabbit 813 immunized with gp120 consensus AE DNA 
prime protein boost. Following this incubation, the membrane was washed with blocking 
buffer every 10 minutes for 1 hour. The membrane was then reacted with AP-conjugated 
goat anti-rabbit IgG at a 1:5000 dilution for 1 hour, and then washed again with blocking 
buffer every 10 minutes for 1 hour. Western-light substrate was applied to the membrane 
for 5 minutes, and then the membrane was dried. To develop the membrane, X-ray films 
were exposed to the membrane and a Kodak processor was used to develop the image.  
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISA assays were used to evaluate the binding of twelve RmAbs with all eleven 
expressed gp120 proteins. These ELISA assays were performed using 96-well microtiter 
plates, and were washed with buffer using a plate washing machine between each step. 
The plates were first incubated with ConA for 1 hour. Then, the plates were coated with 
each purified gp120 antigen in duplicate from the transfected 293F cells at a 
concentration of 1 µg/mL. After 1 hour, the wells were blocked with 200 µl/well of 
blocking buffer, and stored at 4ºC to block overnight. The following day, 100 µl of rabbit 
sera with an RmAb concentration of 1 µg/mL was added in duplicate wells to each gp120 
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antigen and incubated for 1 hour. Then, a coat of biotinylated anti-rabbit IgG at a 1:1000 
dilution was added to the wells as a secondary antibody for 1 hour. Horseradish-
peroxidase (HRP)-conjugated streptavidin at a 1:2000 dilution was then added to the 
wells, which binds to the biotin on the secondary antibody, and the reaction was 
incubated for 1 hour. Freshly-made TMB substrate was added to the wells in the final 
step of the assay, and incubated for 3.5 minutes to change the color of solution in the 
wells blue. The intensity of the blue color is dependent on how much binding of the 
RmAb to the gp120 coat had occurred within the well. The reaction was stopped by 
adding 50 µl of 2 M H2SO4. This color change was quantified by an ELISA plate reader 
at the optical density (OD) of 450 nm (OD450). The OD450 values for the duplicate wells 
were averaged for the final data.  
 
Sequence Analysis 
 
The sequences of all eleven expressed gp120 proteins were aligned using Mac 
Vector to allow for the sequence comparison of the gp120 AE consensus protein versus 
ten other gp120 proteins. The binding sites of all the RmAbs with known possible 
epitopes were located within the sequences to allow for analysis of correlations between 
gp120 protein sequence variations and the binding profiles of RmAbs. 
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RESULTS 
 
 
The results of this project were organized into four main sections. These sections 
are separated as: gp120 purification data, western blot data, ELISA data, and gp120 
sequence alignment data. The sections of ELISA data and gp120 sequence alignment data 
were further analyzed by RmAb epitopes to examine possible correlations between gp120 
sequence variations and RmAb binding profiles. The overall result of this project 
involving all four sections of data is that a gp120 consensus AE DNA-prime protein-
boost vaccine regiment was successful in producing rabbit monoclonal antibodies against 
clade AE HIV-1 gp120 proteins.  
 
gp120 Purification Data 
 
A panel of eleven different expression plasmids encoding eleven different gp120 
proteins was transfected into 293F cells as described in Methods. The gp120 proteins of 
clade AE included in the analysis were as follows: 620345.c01, 620345.c10, 703357.c02, 
427299.c12, 816763.c02, 356272.c02, R2184.c04, R3265.c06, China AE consensus 
(China AE con.), gp120 AE consensus (AE con.). A clade B gp120 protein, JR-FL, was 
also included. The transfected cells were cultured to allow secretion of the gp120 proteins 
into the culture supernatant, then the supernatants were harvested to be used as ELISA 
coating antigens. Purification of gp120 from the supernatant of transfected 293F cells 
was performed to determine the level of expression of all eleven gp120 proteins, and to 
use the purified gp120’s as coats in ELISAs. This purification was performed using the 
protocol outlined in the Materials and Methods section. A lectin column was used to 
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isolate gp120 from each supernatant. The concentration of gp120 protein in each of the 
samples was determined by Nano-Drop.  
SDS-PAGE gels were used to confirm successful purification of each gp120 
protein (Figure 3), and confirmed the presence of purified gp120 in all eleven of the 
samples at 120 kD. 
 
Figure 3: SDS-PAGE Gel to Confirm gp120 Yield.  The gel 
confirmed the presence of gp120 in all eleven of the purified samples 
run at a protein concentration of 5 µg/mL. 
 
 
Western Blot Data 
The levels of purified gp120 proteins were further evaluated by Western blot 
(Figure 4), which indicated strong signals at 120 kDa for all nine gp120 isolates and two 
gp120 consensus proteins. 
 
 
Figure 4: Western Blot to Confirm the gp120 Protein Levels.  The 
western confirmed the presence of gp120 in all eleven of the purified 
samples using RmAb 16 as primary antibody for detection.  
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ELISA and Sequence Analysis Data 
 
ELISA assays were performed to test the binding affinity of the ten RmAbs 
developed in the Lu Lab against all eleven purified gp120 proteins. The results for all 
twelve RmAbs are shown in Table 1, and these results will be further analyzed by 
epitopes in later sections. gp120 proteins JR-FL, ChinaAE consensus, and gp120AE 
consensus had high OD450 values (red, high mAb binding) for most of the RmAbs. Since 
the gp120 AE consensus was used to initially immunize the rabbit receiving the clade AE 
DNA vaccine, it was expected that the RmAbs produced by the clade AE vaccine would 
bind very well to the gp120 AE consensus protein. Both of the clade-B RmAbs, 53 and 
56, also bound very well to gp120 AE consensus protein, despite being produced by the 
clade B JR-FL vaccine. This clade B JR-FL protein elicited strong binding from both 
clade B and clade AE RmAbs. These results suggest that RmAbs able to recognize cross-
clade gp120 proteins were produced. 
 
 
 
Table 1: Average ELISA OD450 Values for all 10 RmAbs Against All 11 Purified 
gp120 Proteins.  Also shown is the data for a PBS negative control. OD450 values 
representing strong binding (≥ 0.60) are highlighted in red and OD450 values representing 
weak to no binding (< 0.39) are highlighted in blue. 
 
 
  
Epitope RmAb 620345.c01 620345.c10 703357.c02 427299.c12 816763.c02 356272.c02 R2184.c04 R3265.c06 JR-FL ChinaAE con. AE con. PBS
80 0.38 0.44 0.45 0.22 0.53 0.46 0.49 0.38 0.76 0.62 0.63 0.05
47 0.45 0.61 0.54 0.55 0.60 0.62 0.51 0.56 0.80 0.76 0.75 0.05
56 0.62 0.69 0.45 0.09 0.06 0.25 0.06 0.05 0.76 0.79 0.82 0.04
16 0.79 0.78 0.71 0.69 0.57 0.40 0.70 0.69 0.81 0.81 0.83 0.05
73 0.72 0.69 0.33 0.57 0.58 0.08 0.53 0.49 0.80 0.81 0.81 0.05
28 0.76 0.51 0.09 0.58 0.52 0.39 0.71 0.72 0.79 0.80 0.80 0.05
64 0.69 0.49 0.10 0.56 0.23 0.07 0.31 0.35 0.82 0.80 0.79 0.05
C4 53 0.25 0.66 0.12 0.15 0.44 0.43 0.67 0.55 0.70 0.72 0.80 0.05
C5 76 0.69 0.66 0.63 0.64 0.76 0.36 0.75 0.75 0.78 0.79 0.63 0.05
Unknown 31 0.58 0.68 0.65 0.60 0.72 0.57 0.70 0.60 0.78 0.71 0.78 0.05
C1
V3
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gp120 Sequence Alignment Data 
Amino acid sequences of these gp120 proteins were used to map the potential 
epitopes recognized by the RmAbs. The sequences of the eleven gp120 proteins were 
aligned using Mac Vector, and the known RmAb epitopes were identified in the gp120 
AE consensus sequence (Table 2). The sera from which the majority of the RmAbs were 
isolated came from the rabbit vaccinated with the gp120 AE consensus, so the RmAbs 
were initially formed against this particular antigen. Therefore, the RmAb epitopes were 
located within the sequence of gp120 AE consensus, and this antigen will be used as a 
basis for comparison with all ten of the other gp120 proteins. All mutations that differ 
from the sequence of gp120 AE consensus are labeled in red, and the four known RmAb 
epitopes were highlighted and color coded.  In the next few sections, these epitopes were 
analyzed in detail with the ELISA data representing the RmAbs that bind each epitope in 
order to identify any possible correlation between gp120 epitope sequence variations and 
RmAb binding affinity. 
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Table 2:  gp120 Sequence Alignment 
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C1-Specific RmAb ELISA and Sequence Analysis 
RmAbs 47and 80 (Table 3) are gp120 C1-specific RmAbs produced by the clade 
AE vaccine. Of these two RmAbs, RmAb 47 bound the strongest to several of the gp120 
proteins. RmAb 80 had reduced or no binding with most of the gp120 proteins. 
 
 
 
Table 3: Average ELISA OD450 values for C1-specific RmAbs 47 and 80 against with all 
11 gp120 proteins and a PBS negative control. OD450 values representing strong binding 
(≥ 0.60) are highlighted in red and OD450 values representing weak to no binding (< 0.39) 
are highlighted in blue. 
 
 
Analyzing the sequence of the C1 epitope, all of the gp120 proteins had identical 
amino acid sequences except for 620345.c01 and 703357.c02 (Figure 5). Both proteins 
had the point mutation V87I, and 703357.c02 had an additional point mutation Q72H.  
Both RmAb 47 and 80 had slightly reduced binding with 620345.c01, so it is possible 
that that the mutation V87I may have interfered with the binding of these RmAbs. RmAb 
80 also had significantly lower binding with 427299.c12 compared to the other gp120 
proteins, which is an interesting result as 427299.c12 had no mutations in this epitope. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: gp120 protein sequence alignment of C1-specific binding site shown as pink. 
Mutations from the original AE con. sequence are shown as red residues. 
 
RmAb 620345.c01 620345.c10 703357.c02 427299.c12 816763.c02 356272.c02 R2184.c04 R3265.c06 JR-FL ChinaAE con. AE con. PBS
80 0.38 0.44 0.45 0.22 0.53 0.46 0.49 0.38 0.76 0.62 0.63 0.05
47 0.45 0.61 0.54 0.55 0.60 0.62 0.51 0.56 0.80 0.76 0.75 0.05
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V3-Specifc RmAb ELISA and Sequence Analysis 
 
RmAbs 56, 16, 73, 28, and 64 are all V3-specific RmAbs. One of these RmAbs, 
56, was produced by the clade B JR-FL vaccine, and the other four were produced by the 
clade AE vaccine. All five of these RmAbs bound very well with JR-FL, China AE 
consensus, and gp120 AE consensus (Table 4). Interestingly, although RmAb 56 was 
produced by the clade B JR-FL vaccine, this RmAb binds equally as well to both of the 
gp120 AE consensus proteins. Likewise, RmAbs 16, 73, 28, and 64 were all produced by 
the clade AE vaccine, but they all bind equally as well to the clade B JR-FL protein. The 
results suggest the potential for cross-clade RmAbs. However, the clade B RmAb 56 did 
not binding very well with most of the clade AE gp120 proteins. Additionally, these five 
RmAbs all had reduced or no measurable binding with 356272.c02. RmAbs 73, 28, and 
64 also had reduced to no binding with 703357.c02. 
 
 
 
Table 4: Average ELISA OD450 values for V3-specific RmAbs 56, 16, 73, 28, and 64 
against all 11 gp120 proteins and a PBS negative control. OD450 values representing 
strong binding (≥ 0.60) are highlighted in red, and OD450 values representing weak to no 
binding (< 0.39) are highlighted in blue. 
 
 
As discovered by the sequence analysis (Figure 6), 703357.c02 and 356272.c02 
had one common point mutation S259T, suggesting that this mutation could be 
interfering with RmAb binding. This mutation is a mutation of the first amino acid of the 
epitope. R2184.c04 only has one point mutation I275M, and RmAbs 56 and 16 have little 
to no measurable binding with this protein. This suggests that the mutation I275M is 
RmAb 620345.c01 620345.c10 703357.c02 427299.c12 816763.c02 356272.c02 R2184.c04 R3265.c06 JR-FL ChinaAE con. AE con. PBS
56 0.62 0.69 0.45 0.09 0.06 0.25 0.06 0.05 0.76 0.79 0.82 0.04
16 0.79 0.78 0.71 0.69 0.57 0.40 0.70 0.69 0.81 0.81 0.83 0.05
73 0.72 0.69 0.33 0.57 0.58 0.08 0.53 0.49 0.80 0.81 0.81 0.05
28 0.76 0.51 0.09 0.58 0.52 0.39 0.71 0.72 0.79 0.80 0.80 0.05
64 0.69 0.49 0.10 0.56 0.23 0.07 0.31 0.35 0.82 0.80 0.79 0.05
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likely interfering with the binding of RmAbs 56 and 16. R3265.c06 has this same point 
mutation, I275M, and RmAbs 56, 73, and 16 have reduced to no binding with this gp120 
protein. 
 
 
Figure 6: gp120 protein sequence alignment of V3-specific binding site shown 
as blue highlighted residues. Mutations from the original AE con. sequence are 
shown as red residues. 
 
 
 
C4-Specifc RmAb ELISA and Sequence Analysis 
 
 There was only one C4-specific RmAb 53 included in this analysis (Table 5). 
This RmAb was produced by the clade B vaccine, and it therefore bound well with the 
clade B JR-FL protein. RmAb 53 also presented with some cross-clade binding, as it 
bound very well with gp120 AE consensus and a few of the individual gp120 proteins. 
RmAb 53 had little measurable binding with 703357.c02 and 427299.c12. 
 
 
 
Table 5: Average ELISA OD450 values for C4-specific RmAb 53 against all 11 gp120 
proteins and a PBS negative control. OD450 values representing strong binding (≥ 0.60) 
are highlighted in red, and OD450 values representing weak to no binding (< 0.39) are 
highlighted in blue. 
 
RmAb 620345.c01 620345.c10 703357.c02 427299.c12 816763.c02 356272.c02 R2184.c04 R3265.c06 JR-FL ChinaAE con. AE con. PBS
53 0.25 0.66 0.12 0.15 0.44 0.43 0.67 0.55 0.70 0.72 0.80 0.05
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From the sequence analysis (Figure 7), both proteins 703357.c02 and 427299.c12 
had a number of mutations with this epitope, so it would be difficult to determine exactly 
which mutations could be affecting the binding of RmAb 53. 427299.c12 has one 
mutation location unique to this protein which is M387L. 703357.c02 also only had one 
mutation location unique to it at A404N. It is possible that these mutations are affecting 
RmAb 53 binding; however it would be impossible to determine this for sure based on 
this data alone. 
 
 
Figure 7: gp120 protein sequence alignment of C4-specific binding site shown as green 
highlighted residues. Mutations from the original AE con. sequence are shown as red 
residues. 
 
C5-Specifc RmAb ELISA and Sequence Analysis 
 
 There was only one C5-specific RmAb included in the analysis, RmAb 76 (Table 
6). This RmAb was produced by the clade AE vaccine. Interestingly, this RmAb had 
strong binding with clade B and clade AE gp120 proteins. However, in general, RmAb 
bound very well to the entire panel of gp120 proteins. The only reduction in binding was 
seen with gp120 protein 35272.c02. 
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Table 6: Average ELISA OD450 values for C5-specific RmAb 76 against all 11 gp120 
proteins and a PBS negative control. OD450 values representing strong binding (≥ 0.60) 
are highlighted in red, and OD450 values representing weak to no binding (< 0.39) are 
highlighted in blue. 
 
 
The only antigen with which RmAb 76 had reduced binding affinity was 
356272.c02. 356272.c02 has two point mutations Q451K and I457L (Figure 8). 
Therefore, it is likely that either of these two mutations, if not both of them, affected the 
binding of RmAb 76. 
 
 
 
Figure 8: gp120 protein sequence alignment of C5-specific binding site shown as yellow 
highlighted residues. Mutations from the original AE con sequences are shown as red 
residues. 
 
Unknown Epitope RmAb ELISA and Sequence Analysis 
 
RmAb 31 has an unknown binding site, so very little site specific analysis can be 
done for this RmAb (Table 7). RmAb 31 was produced by the clade AE vaccine. The 
ELISA results for RmAb 31 resemble those from RmAbs with epitopes located in 
RmAb 620345.c01 620345.c10 703357.c02 427299.c12 816763.c02 356272.c02 R2184.c04 R3265.c06 JR-FL ChinaAE con. AE con. PBS
76 0.69 0.66 0.63 0.64 0.76 0.36 0.75 0.75 0.78 0.79 0.63 0.05
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constant regions of the gp120 sequence, so it is likely this RmAb binds within a 
conformation conserved region as well. 
 
 
 
Table 7: Average ELISA OD450 values for unknown epitope RmAb 31 against all 11 
gp120 proteins and a PBS negative control. OD450 values representing strong binding (≥ 
0.60) are highlighted in red, and OD450 values representing weak to no binding (< 0.39) 
are highlighted in blue. 
 
 
 Overall, the results show that the HIV-1 clade AE gp120 consensus vaccine was 
successful in producing an effective antibody response which can be further dissected 
with a panel of monoclonal antibodies in the vaccinated rabbit. Compared to V3-specific 
RmAbs, RmAbs targeting the conserved region C1, C4, and C5 of HIV-1 gp120 AE 
consensus tends to be recognized by most, if not all, of gp120 proteins cloned from clade 
AE viruses. Despite targeting the same epitope within V3 region, RmAbs16, 73, 28, and 
64 are able to be recognized by more gp120AE proteins, compared to RmAb 53 elicited 
by a clade B vaccine. However, the inclusion of the clade B JR-FLgp120 protein 
demonstrated the possibility of the production of RmAbs able to bind to cross-clade 
gp120 proteins. The results are further discussed in the Discussion section, along with 
suggestions for possible further experiments. 
RmAb 620345.c01 620345.c10 703357.c02 427299.c12 816763.c02 356272.c02 R2184.c04 R3265.c06 JR-FL ChinaAE con. AE con. PBS
31 0.58 0.68 0.65 0.60 0.72 0.57 0.70 0.60 0.78 0.71 0.78 0.05
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DISCUSSION 
 
 
In this study, eight RmAbs generated from a rabbit immunized with an HIV-1 
gp120 AE consensus DNA-prime followed by a gp120 AE consensus protein boost 
vaccination regimen were analyzed for their binding capability against eight different 
recombinant isolates of HIV-1 gp120 clade AE isolates. All of the RmAbs tested were 
able to bind with at least one clade AE gp120 protein, and some of the RmAbs were able 
to bind with most of, if not all, gp120 proteins. This indicates that the gp120 AE 
consensus, despite being an artificially designed protein, was able to generate clade AE-
specific binding antibody responses. Interestingly, two RmAbs generated from a clade B 
JR-FL vaccine, RmAbs 56 and 53, showed a lesser degree of cross-reactivity with gp120 
AE proteins, compared to the RmAbs from the clade AE vaccine, revealing the antigen 
specificity produced by the vaccine. 
            It is evident from the data presented in the results section that the HIV-1 gp120 
AE consensus vaccine regimen was successful in producing a broad spectrum of 
monoclonal antibodies against gp120 in the immunized rabbit, suggesting the potential 
application of this vaccine design. Although not every RmAb produced was effective at 
binding with every gp120 protein studied, there was at least one RmAb capable of 
effectively binding with each of the tested gp120 proteins. Moreover, since these RmAbs 
elicited from gp120 AE vaccines were generated from one rabbit, it is speculated that the 
mixture of circulating RmAbs would eventually complement each other and bind 
with most, if not all, of the gp120 proteins from different clades.  There is also evidence 
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within the results of this project to support the application of this vaccine design for the 
production of RmAbs able to recognize cross-clade gp120 proteins.  
            Potential epitopes for one of the RmAb, 31, are not known. While the results from 
this project may suggest the general locations of these epitopes, further experimentation 
is needed to identify possible epitopes for this RmAb. In addition to binding to diverse 
glycoprotein of clade AE viruses, the other biological functions of these RmAbs, such as 
neutralization activities, will be determined in a future study. 
Previously, most of the immunogenicity studies in this field used polyclonal sera, 
which makes it difficult to link the observed antibody activities with a particular antibody 
component in a polyclonal serum. Here,  the isolation of RmAbs from the vaccine 
provided a valuable opportunity to assess the specificity of their biological activities. For 
example, most of the RmAbs were able to recognize epitopes within constant regions of 
gp120 AE proteins probably due to conservation of the antigen sequence. Some of 
variable-region specific RmAbs, such as RmAb 64, cannot interact with most of the 
gp120 AE proteins. Further, when comparing the sequences of different gp120 AE 
proteins, it helps us to understand, and eventually predict, the binding capability against 
these diverse antigens. 
Genetic diversity and effective evasion of the immune system have made HIV-1 a 
worldwide epidemic, and complicated all means of treatment and prevention so far. With 
the promising results of the RVI44 trial as the first partially-successful vaccine trial 
against HIV, a vaccination method of preventing HIV infection has become a very real 
possibility. The novel technology developed by the Lu Lab of producing rabbit 
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monoclonal antibodies against HIV-1 shows much promise for contributing to this field 
of research. 
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